Compare Cytokinetics Inc (CYTK) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.08 (market cap $3.80B). The key difference: Cytokinetics Inc is far larger — about 2.3× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| CYTK | VNQI | |
|---|---|---|
Market Cap | $8.62B | $3.80B |
Volume | 2,594,626 | 277,049 |
Sector | Health | — |
52-Week High | $87.26 | $50.76 |
52-Week Low | $54.76 | $41.81 |
Typical Hold Time | 19 Days | 95 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $42.08, up 0.63% with bearish technical signals from moving averages. The ETF provides international real estate exposure across 30+ countries, offering a higher dividend yield than domestic alternatives. Recent news highlights a significant 45.9% drop in short interest in September 2026, while technical indicators show oversold conditions with RSI readings below 30.
The ETF faces headwinds from global real estate market volatility but offers diversification benefits and income potential. Key risks include international currency exposure and regional economic uncertainties. The substantial decline in short interest suggests potential sentiment improvement, though technical trends remain bearish near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
